[Empiric therapy with aztreonam for febrile neutropenic patients with hematological malignancies].
Combination of aztreonam/amikacin/ticarcillin (AAT) and latamoxef/amikacin/ticarcillin (LAT) were compared in a prospective randomized trial of empiric therapy for febrile neutropenic patients with hematological malignancies. Low dose amphotericin B was also added to each regimen from the beginning. Of 45 evaluable episodes, 23 were treated with AAT and 22 with LAT. The response rates were 61 percent for AAT and 50 percent for LAT, statistically not significant. There was one infection-related death among patients assigned to AAT therapy and also one among those assigned to LAT therapy. Dose escalation of amphotericin B seemed to be effective for those patients who did not improve with initial therapy.
Moriuchi
Y
Y
Soda
H
H
Toriya
K
K
Tomonaga
M
M
Ichimaru
M
M
D001398:Aztreonam / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005334:Fever / Q000209:etiology; D006801:Humans; D007239:Infections / Q000188:drug therapy*; D007938:Leukemia / Q000150:complications*; D008223:Lymphoma / Q000150:complications*; D009503:Neutropenia / Q000150:complications
D001398:Aztreonam